Navigation Links
Single gene mutation induces endometrial cancer
Date:2/9/2010

DALLAS Feb. 10, 2010 A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study.

The finding suggests that eventually it might be possible to screen women with endometrial cancer to see if they have that mutation and use the drug as targeted therapy, the researchers said.

"Our data suggest that deficiency of this gene can indicate both how aggressive an endometrial tumor will be and how well it might respond to a specific class of drugs," said Dr. Diego Castrillon, assistant professor of pathology at UT Southwestern and senior author of the paper, which appears in the March/April issue of Disease Models and Mechanisms.

"Some early clinical trials have shown that about one-fifth of women with endometrial cancers respond to a group of drugs called 'rapalogs,'" Dr. Castrillon said. "Unfortunately, it is not currently possible to predict which women these are."

Endometrial cancer affects the lining of the uterus. This cancer is the most common cancer of the female reproductive tract and is usually detected when a woman complains of excessive bleeding. About one-third of ovarian cancer cases are believed to begin as endometrial cancer, Dr. Castrillon said. The median survival of women with advanced endometrial cancer is one year.

The researchers focused the gene Lkb1, which is known to suppress other types of cancers. Mutations in Lkb1 disrupt its "braking" action on cancer and contribute to the disease in lungs, skin and other tissues.

In the current study, the researchers genetically engineered mice to inactive Lkb1 only in the endometrium. Without Lkb1, the entire endometrium became cancerous early and rapidly, they found.

The researchers found that treating the cancerous mice with the anti-cancer drug rapamycin slowed the progression of the cancers and dramatically shrank existing tumors.

"We hope that someday a test based on this gene or others like it might pinpoint which women would respond best to treatment with 'rapalogs,'" Dr. Castrillon said. "Such personalized medicine could spare other women from unnecessary chemotherapy if their tumors are unresponsive to the drugs."

Other UT Southwestern researchers participating in the study were graduate students Cristina Contreras and Esra Akbay; senior research scientist Teresa Gallardo; research assistant Marshall Haynie; Dr. Masaya Takahashi, associate professor in UT Southwestern's Advanced Imaging Research Center; and Dr. Osamu Togao, postdoctoral research fellow in the Advanced Imaging Research Center.

Researchers at Harvard Medical School also participated in the study.

The research was supported by the National Cancer Institute, a Translational Science Award from the Sidney Kimmel Foundation for Cancer Research, the American Cancer Society, and the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.


'/>"/>
Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
2. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
5. International Watchdog Group Singles Out Resurrection for Anti-Union Violations
6. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
7. Married esophageal cancer patients fare worse in some quality of life aspects than single patients
8. Verathon Inc. Introduces GlideScope(R) Ranger Single Use Video Laryngoscope for Emergency Departments, EMS and Military; Enables Fast Intubations and Eliminates Time-Consuming Disinfection
9. National Nurses Movement Lauds Al Gore for Leadership on Single-Payer Healthcare
10. Methodist Health System Foundation Announces Largest Single Gift
11. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... The International Essential Tremor Foundation (IETF) will host a free ... The seminar will take place on Saturday, Aug. 26 at the Embassy Suites by ... run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. The ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care ... one of the leading causes of long term skin conditions, including cancer. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... fat (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 ... its adipose filtration technology. The '398 and '324 patents cover methods and ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Sharon Kleyne, host ... and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the ... of myopia in China. , The article by Zidor Aldama described the situation in ...
(Date:7/24/2017)... ... 2017 , ... A Southern California-based author has released a new book which ... has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights the ... above. , In “Memories,” readers get a firsthand look at what Michelle has been ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
Breaking Medicine Technology: